21629-50-5 Usage
General Description
5-CHLORO-2,8-DIMETHYL-4-QUINOLINOL, also known as nitroxoline, is a synthetic antibacterial and antifungal agent that is primarily used to treat urinary tract infections. It is classified as a quinolone antibiotic and works by inhibiting the growth of bacteria and fungi in the urinary tract. The compound has a broad spectrum of activity against various pathogens, including Escherichia coli, Staphylococcus aureus, and Candida species. Its chemical structure consists of a quinoline ring with a chlorine atom at the 5-position and methyl groups at the 2- and 8-positions. Nitroxoline is available in oral formulations and is generally well-tolerated, with common side effects including gastrointestinal upset and skin reactions. Due to its effectiveness and low resistance development, nitroxoline remains a valuable option for the treatment of urinary tract infections.
Check Digit Verification of cas no
The CAS Registry Mumber 21629-50-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,1,6,2 and 9 respectively; the second part has 2 digits, 5 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 21629-50:
(7*2)+(6*1)+(5*6)+(4*2)+(3*9)+(2*5)+(1*0)=95
95 % 10 = 5
So 21629-50-5 is a valid CAS Registry Number.
InChI:InChI=1/C11H10ClNO/c1-6-3-4-8(12)10-9(14)5-7(2)13-11(6)10/h3-5H,1-2H3,(H,13,14)
21629-50-5Relevant articles and documents
N1-{4-[(10S)-Dihydroartemisinin-10-oxyl]}phenylmethylene-N 2-(2-methylquinoline-4-yl)hydrazine derivatives as antiplasmodial falcipain-2 inhibitors
Luo, Wei,Liu, Yang,Wang, Jian,Guo, Chun,Lu, Wei-Qiang,Cui, Kun-Qiang
, p. 3073 - 3079,7 (2020/08/20)
A series of N1-{4-[(10S)-dihydroartemisinin- 10-oxyl]}phenylmethylene-N2-(2-methylquinoline-4-yl) hydrazine derivatives 9a-9n possessing 4-quinolylhydrazone and artemisinin cores were herein synthesized and evaluated for their activities against cysteine protease falcipain- 2 of Plasmodium falciparum. The structures were clearly confirmed by elemental analysis, 1H NMR, and mass spectra. The pharmacological results indicated that all compounds showed excellent activity against recombinant falcipain-2 (IC50 = 0.15-2.28 μM). The best one of this series was compound 9d (IC50 = 0.15 μM). The molecular docking results showed that the compound 9d made close contact with the key active site of cysteine protease falcipain-2.